Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzi...
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings with...
Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical G...
* Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a...
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ)...
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effo...
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor mic...
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis ...
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales...
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk predi...
Follow-up to ScreenTrustCAD presented at RSNA 2024 highlights 1-year post-AI adoption success in im...
* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's ...
Twenty studies validate AI performance across diverse populations and clinical settings, including ...
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-...
Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, ...
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment out...
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading env...
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker fo...
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pa...
* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guid...
